Dakshidin Corporation, Inc.

OTCPK:DKSC Stock Report

Market Cap: US$3.6m

Dakshidin Corporation Past Earnings Performance

Past criteria checks 0/6

No hay datos suficientes sobre los resultados de Dakshidin en los últimos años.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth raten/a
Return on equityn/a
Net Marginn/a
Earnings Updaten/a

Recent past performance updates

No updates

Recent updates

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Dakshidin Corporation has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.

Show section

Revenue & Expenses Breakdown
Beta

How Dakshidin Corporation makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:DKSC Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses

Beneficios de calidad: Datos insuficientes para determinar si DKSC tiene ganancias de alta calidad.

Creciente margen de beneficios: No hay datos suficientes para determinar si los márgenes de beneficio de DKSC han mejorado en el último año.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Tendencia de beneficios: No se ha podido determinar si la tasa de crecimiento interanual de los beneficios de DKSC ha sido positiva en los últimos 5 años, ya que cotiza en bolsa desde hace menos de 3 años.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios del último año de DKSC con su media de 5 años, ya que lleva cotizando menos de 3 años.

Beneficios vs. Industria: Datos insuficientes para determinar si el crecimiento de los beneficios de DKSC en el último año superó la media del sector Pharmaceuticals.


Return on Equity

Alto ROE: DKSC tiene un Rendimiento de los fondos propios negativo (0%), ya que actualmente no es rentable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.